HenryBKoonJr.MD
Oncology • Lawrenceville, NJHematologic Oncology, Melanoma, Sarcoma
Clinical Trial Lead, Melanoma
Dr. Koon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Bristol Myers Squibb
3401 Princeton Pike
Lawrenceville, NJ 08648
Summary
- Dr. Henry Koon is an oncologist in Lawrenceville, NJ. He received his medical degree from University of Mississippi School of Medicine and has been in practice 23 years. He specializes in hematologic oncology and is experienced in sarcomas, melanoma and cutaneous malignancies.
Education & Training
University of Mississippi Medical CenterResidency, Internal Medicine, 1994 - 1997- University of Mississippi School of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 2007 - 2026
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma Start of enrollment: 1999 Feb 01
- Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2003 May 01
- Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2005 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 154 citationsAdjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.Dean F Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama
The New England Journal of Medicine. 2021-06-02 - 13 citationsImmune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen
Journal for Immunotherapy of Cancer. 2021-05-01 - 4 citationsPhase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R. Eads, Smitha S. Krishnamurthi, Joel N. Saltzman, Joseph A. Bokar, P. Savvides
Investigational New Drugs. 2021-02-01
Press Mentions
Leap Therapeutics Presents Data from Phase 1 Study of GITR AgonistNovember 12th, 2016- Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual MeetingJune 5th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
